The combination drug market for dyslipidemia treatment using the atorvastatin+ ezetimibe combination has increased twofold with the sudden growth of its generics. Moreover, the market share of the generics exceeded that of the original in Q1 of this year.

The rapid expansion of the market last year is interpreted to be due to more than 100 companies joining in the competition after receiving approvals for their generics last year.

◆Atozet market increase twofold in 1 year due to entry of generics

According to the market research institution UBIST on the 28th, outpatient prescriptions of atorvastatin+ ezetimibe combination drugs recorded ₩44 billion in Q1. Thi